SCHEMBL5312911

SCHEMBL5312911

COCc1nc(-c2ccc(N)cc2)no1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 0.57
MAPT P10636 9/20 0.50
RAB9A P51151 6/20 0.50
HPGD P15428 4/20 0.50
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 3/20 0.50
HSD17B10 Q99714 3/20 0.50
LMNA P02545 1/20 0.50
NPC1 O15118 5/20 0.49
L3MBTL1 Q9Y468 4/20 0.49
TDP1 Q9NUW8 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
NPSR1 Q6W5P4 1/20 0.48
TSHR P16473 5/20 0.48
POLB P06746 1/20 0.48
NOTUM Q6P988 1/20 0.47
HTT P42858 1/20 0.47
NPY1R P25929 1/20 0.47
NPY2R P49146 1/20 0.47
SIRT2 Q8IXJ6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19187518 0.85 MAPT (0.65) MAPK1MAPTRAB9AHPGDALDH1A1
SCHEMBL14441200 0.84 MAPK1 (0.54) MAPK1MAPTRAB9AHPGDALDH1A1
SCHEMBL17278354 0.84 NPC1 (0.63) MAPK1MAPTRAB9AHPGDALDH1A1
SCHEMBL2089122 0.83 RAB9A (0.69) MAPK1MAPTRAB9AHPGDALDH1A1
SCHEMBL201423 0.81 NOTUM (0.56) MAPK1RAB9ALMNANPC1L3MBTL1
SCHEMBL5311162 0.81 ACACB (0.59) MAPTRAB9AHPGDALDH1A1HSD17B10
SCHEMBL12021873 0.80 MAPK1 (0.56) MAPK1MAPTRAB9AHPGDALDH1A1
SCHEMBL15379098 0.79 RAB9A (0.54) RAB9AALDH1A1LMNANPC1TDP1
SCHEMBL10914161 0.79 RAB9A (0.69) MAPTRAB9ANPC1L3MBTL1TDP1
SCHEMBL5469179 0.78 MAPT (0.70) MAPK1MAPTRAB9AHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 US disclosed
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 US disclosed
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 US disclosed
WO-2007053094-A1 CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS ASTRAZENECA AB (SE) 2007-05-10 WO disclosed
WO-2007053094-A1 CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS ASTRAZENECA AB (SE) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135442-A1 Chroman compounds CYP3A43, CYP2C9, CYP2C8 MAPK1 2276/4885MAPT 3096/4885RAB9A 614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.